Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.
about
Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.Pneumococcal antibody concentrations of subjects in communities fully or partially vaccinated with a seven-valent pneumococcal conjugate vaccinePneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine boosterOpsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.Reduced IL-17A Secretion Is Associated with High Levels of Pneumococcal Nasopharyngeal Carriage in Fijian Children.Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.Capsule Switching and Antimicrobial Resistance Acquired during Repeated Streptococcus pneumoniae Pneumonia Episodes.Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on reduced-dosage regimens.Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimesPotential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introductionSystematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makersThe differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity.Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children.The cost of outpatient pneumonia in children <5 years of age in Fiji.Effect of pneumococcal vaccination on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus in Fijian children.Pediatric osteoarticular infections caused by Streptococcus pneumoniae before and after the introduction of the heptavalent pneumococcal conjugate vaccine.Evaluation of different infant vaccination schedules incorporating pneumococcal vaccination (The Vietnam Pneumococcal Project): protocol of a randomised controlled trial.
P2860
Q33605125-DFD8C0DF-35BC-49F9-A485-31EBDC7FCC16Q33788106-A7F419A5-F307-4C5E-8FB1-508AE03E0987Q33803550-EE902AB1-FC19-4A3F-AEA7-EC060A7E5AF3Q34391186-941AB392-4F60-4736-A5E5-91F896819124Q34431928-C826DEC7-0686-4FBD-89B8-CEA2536459EAQ34444503-948AEAE0-C7ED-410C-A5F2-3D285050F4AFQ35042732-D09EF292-A841-40CF-A432-BCBDD3251B53Q35662232-80F8D7F4-0CDB-4187-980D-0DAE154EBA16Q35868890-FDEDB19D-C757-48EB-9188-4C35F23DC5BEQ36066860-869B2199-A9CE-48F3-8016-23F54860D819Q36105725-9767FB7A-02EE-4A37-AF36-F185109DC3EFQ36174421-E3CE7933-6E9E-4A1C-BA38-AD1302BED3CAQ37162391-F80A3DBB-88B8-4976-8DCF-919C2D6AC50AQ37613613-28B1A526-1651-4806-AD24-3501B6E67EB3Q37613616-B34D8B78-B4E1-4880-B52F-1ED55994897FQ37621061-304E92E0-5B95-4B3C-B73C-C1C0DE7B51FCQ37621064-3BBDF295-B10A-455D-8300-E694C29FB6CEQ39516725-381A37F8-FCE3-43F7-B7E7-37596857922DQ42597446-0A762926-5735-4423-A398-07CA774C455BQ44135641-B3766C1A-663F-4471-BF83-1D1D43788B9CQ55313306-DEBD723E-9AE1-4A0D-84C4-D325BE6EE21A
P2860
Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunogenicity following one, ...... neumococcal conjugate vaccine.
@en
Immunogenicity following one, ...... neumococcal conjugate vaccine.
@nl
type
label
Immunogenicity following one, ...... neumococcal conjugate vaccine.
@en
Immunogenicity following one, ...... neumococcal conjugate vaccine.
@nl
prefLabel
Immunogenicity following one, ...... neumococcal conjugate vaccine.
@en
Immunogenicity following one, ...... neumococcal conjugate vaccine.
@nl
P2093
P2860
P1433
P1476
Immunogenicity following one, ...... pneumococcal conjugate vaccine
@en
P2093
A W J Jenney
E K Mulholland
F M Russell
J R Carapetis
L Tikoduadua
L Waqatakirewa
M L K Tang
P2860
P304
P356
10.1016/J.VACCINE.2009.06.098
P407
P577
2009-07-17T00:00:00Z